Capnia Reports Fourth Quarter and Full Year 2014 Financial Results

REDWOOD CITY, Calif., March 10, 2015 -- Capnia, Inc. (CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced financial results for the fourth quarter and twelve months ended December 31, 2014.

"Capnia completed several important milestones in 2014, including a successful initial public offering and the launch of CoSense(R), the only device available for accurate assessment of end-tidal carbon monoxide (ETCO) in newborns," said Anish Bhatnagar, M.D., Chief Executive Officer of Capnia. "The commercial rollout of CoSense is proceeding in the U.S. We also continue to evaluate the potential of our therapeutic nasal CO2 technology for the treatment of symptomatic allergic rhinitis, cluster headache and trigeminal neuralgia (TN). This is an exciting time for the Company, and we look forward to communicating our progress throughout 2015."

Published: 11 March 2015
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Capnia Inc ( CAPN )

Digirad Corporation Acquires MD Office Solutions, Inc.

  • Mobile Diagnostic Imaging Business based in Northern California
  • Opens Up a New Mobile Imaging Market for Digirad

SUWANEE, Ga., March 6, 2015 -- Digirad Corporation (DRAD), the leader in providing diagnostic imaging services and technology on an as needed, when needed and where needed basis, announced today that it acquired MD Office Solutions, Inc. ("MD Office"), a mobile diagnostic imaging provider servicing customers in Northern California.

Digirad President and CEO Matthew G. Molchan commented, "As we have been discussing over the last year, one component of our growth strategy is to complete disciplined, tuck-in acquisitions within our core businesses.

Published: 06 March 2015
Written by Editor
Nasdaq   M & A   Up on News  
Read more: Digirad Corporation ( DRAD )

Study Highlights Value of Biocept's Blood-Based Diagnostic for Determining Hormonal Status in Patients With Metastatic Breast Cancer

SAN DIEGO, Feb. 23, 2015  -- Biocept, Inc. (BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that its blood-based diagnostic, OncoCEE-BR(TM), was used to determine hormonal status of metastatic breast cancer patients in a prospective study performed at the Columbia University College of Physicians and Surgeons in New York City. Findings from the Columbia study were recently published in the peer-reviewed journal Clinical and Translational Oncology.

Published: 23 February 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Biocept Inc ( BIOC )

Superior Court Issues Tentative Ruling and Proposed Statement of Decision in Favor of CombiMatrix

Parties Have 15 Days to File Objections

IRVINE, Calif., Jan. 6, 2015  -- CombiMatrix Corporation (CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that the Superior Court of the State of California, County of Orange (the "Court"), has issued a tentative ruling and proposed statement of decision (the "Proposed Statement of Decision") in the matter of the People of the State of California and Relator Michael Strathmann ("Plaintiff") vs. Acacia Research Corporation, CombiMatrix Corporation and Amit Kumar ("Defendants"). In its 27-page Proposed Statement of Decision, the Court has tentatively ruled in favor of the Defendants and against all claims of the Plaintiff. Specifically, the Court determined that Defendants had no fraudulent intent when they pursued insurance benefits under the National Union D&O Policy over a decade ago. Each party in this case now has up to fifteen days to file any objections it may have. The Court then has approximately 60 days to consider the objections and to hear additional arguments before the Court issues its final ruling and judgment.

Published: 06 January 2015
Written by Editor
Nasdaq   Up on News  
Read more: CombiMatrix Corporation ( CBMX )

Akers Biosciences Announces $1 Million Initial Order to Supply PIFA Heparin/PF4 Products to China

THOROFARE, N.J., Dec. 10, 2014 -- Akers Biosciences, Inc. (AKER) (AIM:AKR.L), (the "Company"), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the receipt of an initial purchase order (the "Order") valued at US$1,000,000 from NovoTek Therapeutics Inc. ("NovoTek") to supply PIFA Heparin PF4/Rapid Assay products in Mainland China ("China").

NovoTek, a Beijing-based pharmaceutical and medical device business development company, holds the exclusive sales and marketing rights for the Company's PIFA Heparin/PF4 Rapid Assay products in China. The Company expects to deliver the Order by December 31, 2014.

Published: 10 December 2014
Written by Editor
Nasdaq   New Product or Order   Up on News  
Read more: Akers Biosciences Inc ( AKER )
  1. Chembio Diagnostics Inc ( CEMI )
  2. CombiMatrix Corporation ( CBMX )
  3. Exact Sciences Corp ( EXAS )
  4. CombiMatrix Corporation ( CBMX )
  5. AMAG Pharmaceuticals Inc ( AMAG )